We would like to take this opportunity to provide an important update related to Myozyme® (alglucosidase alfa) manufacturing in the United States. The FDA has informed Genzyme of its decision on the application for the larger scale manufacturing process to commercially supply Myozyme in the US. The FDA has decided that Myozyme produced at the smaller bioreactor scale (160 L) and at the larger scale (2000 L) should be classified as two different products based on a comparison of biochemical characteristics of the product produced at the two scales. We at Genzyme are disappointed in this decision. Genzyme believes that both products are clinically effective and safe. The product from the smaller scale was used in the pivotal trials supporting FDA approval of Myozyme. The product from the larger scale is approved in 41 countries and is currently used to treat approximately 900 patients of all ages throughout the world including the 138 adults in the US who are currently accessing Myozyme through the Myozyme Temporary Access Program (MTAP).

Genzyme will submit a separate biologics license application (BLA) that includes the positive Late Onset Treatment Study (LOTS) clinical trial results obtained using the larger scale product. Genzyme plans to submit the application by June for priority review and expects to be able to act on an FDA decision in the first quarter of 2009. The FDA continues to support the use of the larger scale product under the MTAP program during this unanticipated extended review period.

Over the past year, the MTAP program has served its intended purpose of allowing Genzyme to offer therapy to adults while maintaining uninterrupted access to commercial treatment for all infants and children in the US. MTAP was specifically created to bridge Myozyme availability until the expected approval of product manufactured at the larger scale. Genzyme has been able to make Myozyme available through MTAP or through regular commercial channels to all patients who had previously been on therapy, and some additional new patients who met specific enrollment criteria, prior to the delay in the FDA approval of the 2000 L product. In light of the FDA’s decision, what was originally anticipated to be a temporary situation will now take much longer than expected to resolve.

As a result, the following measures are being implemented and are effective immediately:

- The MTAP program is closed to new patients.
- Any physician who feels that their adult patient is in critical need of treatment should contact Genzyme Medical Information at 1-800-745-4447, option 2.
- Patients currently enrolled in MTAP will continue to access treatment via this clinical program.
- LOTS extension trial participants will continue to transition into MTAP as planned after completion of that study.
- Infants and children aged 17 and younger will continue to access treatment via regular commercial channels.

We will be re-evaluating our ability to sustain the existing MTAP program, continue to monitor the commercial supply closely, and keep you updated on any further developments or changes that may be required.

Please know that we fully appreciate the consequences this news has to the Pompe Community. We will continue to work with you to identify any and all possible channels that may be available for patients to access treatment while we await approval of the larger scale product. Our commitment to provide
treatment to all those in need remains unchanged. We are confident that any delay or potential disruption to supply will only be temporary and Genzyme will continue to work to improve access to Myozyme.